Chronic lymphocytic leukemia diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 11: Line 11:
Chronic lymphocytic leukemia is diagnosed according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines:<ref name="pmid29540348">{{cite journal |vauthors=Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ |title=iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL |journal=Blood |volume=131 |issue=25 |pages=2745–2760 |date=June 2018 |pmid=29540348 |doi=10.1182/blood-2017-09-806398 |url=}}</ref><ref name="pmid3189311">{{cite journal |vauthors=Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ |title=Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group |journal=Am. J. Hematol. |volume=29 |issue=3 |pages=152–63 |date=November 1988 |pmid=3189311 |doi= |url=}}</ref>
Chronic lymphocytic leukemia is diagnosed according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines:<ref name="pmid29540348">{{cite journal |vauthors=Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ |title=iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL |journal=Blood |volume=131 |issue=25 |pages=2745–2760 |date=June 2018 |pmid=29540348 |doi=10.1182/blood-2017-09-806398 |url=}}</ref><ref name="pmid3189311">{{cite journal |vauthors=Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ |title=Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group |journal=Am. J. Hematol. |volume=29 |issue=3 |pages=152–63 |date=November 1988 |pmid=3189311 |doi= |url=}}</ref>
* Complete blood count (CBC) with differential: Absolute lymphocytosis ≥5000 B-lymphocytes/µL X ≥ 3 months
* Complete blood count (CBC) with differential: Absolute lymphocytosis ≥5000 B-lymphocytes/µL X ≥ 3 months
* Flow cytometry: B lymphocytes clonality (Immunoglobulin light chain restriction)  
* Flow cytometry: B lymphocytes clonality (Immunoglobulin light chain restriction)<ref name="pmid29024461">{{cite journal |vauthors=Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E |title=Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project |journal=Cytometry B Clin Cytom |volume=94 |issue=1 |pages=121–128 |date=January 2018 |pmid=29024461 |pmc=5817234 |doi=10.1002/cyto.b.21595 |url=}}</ref>
Presence of clonal B-lymphocutosis <5000/µL without cytpenia, hepatosplenomegaly, lymphadenopathy or other disease-related symptoms can be defined as monoclonal B lymphocytosis (MBL). MBL will progress to CLL at a rate of 1% to 2% per year.<ref name="pmid18687638">{{cite journal |vauthors=Rawstron AC, Bennett FL, O'Connor SJ, Kwok M, Fenton JA, Plummer M, de Tute R, Owen RG, Richards SJ, Jack AS, Hillmen P |title=Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia |journal=N. Engl. J. Med. |volume=359 |issue=6 |pages=575–83 |date=August 2008 |pmid=18687638 |doi=10.1056/NEJMoa075290 |url=}}</ref>
Presence of clonal B-lymphocutosis <5000/µL without cytpenia, hepatosplenomegaly, lymphadenopathy or other disease-related symptoms can be defined as monoclonal B lymphocytosis (MBL). MBL will progress to CLL at a rate of 1% to 2% per year.<ref name="pmid18687638">{{cite journal |vauthors=Rawstron AC, Bennett FL, O'Connor SJ, Kwok M, Fenton JA, Plummer M, de Tute R, Owen RG, Richards SJ, Jack AS, Hillmen P |title=Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia |journal=N. Engl. J. Med. |volume=359 |issue=6 |pages=575–83 |date=August 2008 |pmid=18687638 |doi=10.1056/NEJMoa075290 |url=}}</ref>
*  
*  

Revision as of 00:02, 7 February 2019

Chronic lymphocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chronic lymphocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic lymphocytic leukemia diagnostic study of choice On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic lymphocytic leukemia diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic lymphocytic leukemia diagnostic study of choice

CDC on Chronic lymphocytic leukemia diagnostic study of choice

Chronic lymphocytic leukemia diagnostic study of choice in the news

Blogs on Chronic lymphocytic leukemia diagnostic study of choice

Directions to Hospitals Treating Chronic lymphocytic leukemia

Risk calculators and risk factors for Chronic lymphocytic leukemia diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Overview

The diagnostic study of choice in chronic lymphocytic leukemia is according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines which involves complete blood count (CBC) with differential and peripheral smear flow cytometry.

Diagnostic study of choice

The diagnostic study of choice in chronic lymphocytic leukemia is peripheral blood flow cytometry. If peripheral blood flow cytometry shows greater than 5000 clonal B cell per microliter, the diagnosis is confirmed. Ancillary tests include bone marrow biopsy and peripheral blood cytogenetics or FISH studies.

Chronic lymphocytic leukemia is diagnosed according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines:[1][2]

  • Complete blood count (CBC) with differential: Absolute lymphocytosis ≥5000 B-lymphocytes/µL X ≥ 3 months
  • Flow cytometry: B lymphocytes clonality (Immunoglobulin light chain restriction)[3]

Presence of clonal B-lymphocutosis <5000/µL without cytpenia, hepatosplenomegaly, lymphadenopathy or other disease-related symptoms can be defined as monoclonal B lymphocytosis (MBL). MBL will progress to CLL at a rate of 1% to 2% per year.[4]

References

  1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ (June 2018). "iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL". Blood. 131 (25): 2745–2760. doi:10.1182/blood-2017-09-806398. PMID 29540348.
  2. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ (November 1988). "Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group". Am. J. Hematol. 29 (3): 152–63. PMID 3189311.
  3. Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E (January 2018). "Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project". Cytometry B Clin Cytom. 94 (1): 121–128. doi:10.1002/cyto.b.21595. PMC 5817234. PMID 29024461.
  4. Rawstron AC, Bennett FL, O'Connor SJ, Kwok M, Fenton JA, Plummer M, de Tute R, Owen RG, Richards SJ, Jack AS, Hillmen P (August 2008). "Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia". N. Engl. J. Med. 359 (6): 575–83. doi:10.1056/NEJMoa075290. PMID 18687638.